6,805 reports of this reaction
1.6% of all DULOXETINE HYDROCHLORIDE reports
#17 most reported adverse reaction
HYPERHIDROSIS is the #17 most commonly reported adverse reaction for DULOXETINE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 6,805 FDA adverse event reports linking DULOXETINE HYDROCHLORIDE to HYPERHIDROSIS. This represents approximately 1.6% of all 434,529 adverse event reports for this drug.
Patients taking DULOXETINE HYDROCHLORIDE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for DULOXETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for DULOXETINE HYDROCHLORIDE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 6,805 FDA reports for DULOXETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.6% of all adverse event reports for DULOXETINE HYDROCHLORIDE, making it a notable side effect.
If you experience hyperhidrosis while taking DULOXETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.